SCHEMBL22804532

SCHEMBL22804532

COC(=O)CCC(=O)SCCNC(C)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.48
ALDH1A1 P00352 1/20 0.47
MTNR1A P48039 5/20 0.44
MTNR1B P49286 5/20 0.44
KDM4E B2RXH2 2/20 0.42
MAPK1 P28482 1/20 0.42
HIF1A Q16665 1/20 0.42
ZDHHC7 Q9NXF8 1/20 0.41
KMT2A Q03164 1/20 0.41
ADRA1A P35348 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23922522 0.89 TSHR (0.60) TSHRALDH1A1MTNR1AMTNR1BKDM4E
SCHEMBL22814923 0.85 TSHR (0.44) TSHRALDH1A1MTNR1AMTNR1BKDM4E
SCHEMBL22814968 0.83 TSHR (0.43) TSHRALDH1A1MTNR1AMTNR1BKDM4E
SCHEMBL17164980 0.81 ADRA1A (0.55) TSHRALDH1A1MTNR1AMTNR1BKDM4E
SCHEMBL22814925 0.81 TSHR (0.41) TSHRALDH1A1MTNR1AMTNR1BKDM4E
SCHEMBL17169898 0.80 TSHR (0.40) TSHRALDH1A1MTNR1AMTNR1BKDM4E
SCHEMBL16260817 0.79 TSHR (0.54) TSHRALDH1A1MTNR1AMTNR1BKDM4E
SCHEMBL25587742 0.78 TSHR (0.56) TSHRALDH1A1KDM4EKMT2ACA12
SCHEMBL18734790 0.78 TSHR (0.62) TSHRALDH1A1MTNR1AMTNR1BKDM4E
SCHEMBL15241525 0.78 ZDHHC7 (0.54) TSHRALDH1A1MTNR1AMTNR1BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113993842-B Succinate prodrugs, compositions comprising succinate prodrugs and uses thereof 爱博利瓦有限公司 2024-07-16 CN claimed
EP-4360708-A2 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva AB (SE) 2024-05-01 EP claimed
EP-3986862-B1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva Ab (SE) 2024-01-24 EP claimed
US-20230033294-A1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva Ab (SE) 2023-02-02 US claimed
US-11565998-B2 Succinate prodrug, compositions containing the succinate prodrug and uses thereof Abliva Ab (SE) 2023-01-31 US claimed
US-20220162162-A1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva Ab (SE) 2022-05-26 US claimed
EP-3986862-A1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva AB (SE) 2022-04-27 EP claimed
WO-2020254484-A1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva Ab (SE) 2020-12-24 WO claimed
JP-2025004155-A SUCCINATE PRODRUG, COMPOSITIONS CONTAINING SUCCINATE PRODRUG AND USES THEREOF アブリバ エービー 2025-01-14 JP disclosed
US-12162824-B2 Succinate prodrug, compositions containing the succinate prodrug and uses thereof Abliva Ab (SE) 2024-12-10 US disclosed
CN-113993842-B Succinate prodrugs, compositions comprising succinate prodrugs and uses thereof 爱博利瓦有限公司 2024-07-16 CN disclosed
EP-4360708-A2 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva AB (SE) 2024-05-01 EP disclosed
EP-3986862-B1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva Ab (SE) 2024-01-24 EP disclosed
EP-3986862-B1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva Ab (SE) 2024-01-24 EP disclosed
US-20220162162-A1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva Ab (SE) 2022-05-26 US disclosed
US-20220162162-A1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva Ab (SE) 2022-05-26 US disclosed
EP-3986862-A1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva AB (SE) 2022-04-27 EP disclosed
CN-113993842-A Succinate prodrugs, compositions comprising succinate prodrugs and uses thereof 爱博利瓦有限公司 2022-01-28 CN disclosed
WO-2020254484-A1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva Ab (SE) 2020-12-24 WO disclosed
WO-2020254484-A1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF Abliva Ab (SE) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162162-A1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF CS, SLC25A1, SLC8B1 TSHR 4547/4885ALDH1A1 1333/4885MTNR1A 1083/4885
US-11565998-B2 Succinate prodrug, compositions containing the succinate prodrug and uses thereof CS, SLC25A1, SLC8B1 TSHR 4547/4885ALDH1A1 1333/4885MTNR1A 1083/4885
US-12162824-B2 Succinate prodrug, compositions containing the succinate prodrug and uses thereof CS, SLC25A1, SUCNR1 TSHR 4628/4885ALDH1A1 1362/4885MTNR1A 967/4885
US-20230033294-A1 SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF CS, SLC25A1, SUCNR1 TSHR 4628/4885ALDH1A1 1362/4885MTNR1A 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.